Efficacy and Tolerability of Combination Antihypertensive Drug in Non-Responders to Angiotensin Receptor Blocker(ARB) monoTHerapy Using 24h ABPM

Trial Profile

Efficacy and Tolerability of Combination Antihypertensive Drug in Non-Responders to Angiotensin Receptor Blocker(ARB) monoTHerapy Using 24h ABPM

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Nov 2015

At a glance

  • Drugs Olmesartan medoxomil/amlodipine (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms EARTH
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Nov 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 19 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top